Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6337-6344

  Liu, Xiyong ^a   Zhou, Bingsen ^a   Xue, Lijun ^a   Shih, Jennifer ^a   Tye, Karen ^a   Lin, Wesley ^a   Qi, Christina ^a   Chu, Peiguo ^a   Un, Frank ^a   Wen, Wei ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIGEL; PROTEIN P53; PROTEIN P53 R 2; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL SELECTION; COLON ADENOCARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK; RNA INTERFERENCE; TISSUE MICROARRAY; UNIVARIATE ANALYSIS; WILD TYPE;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33751275310     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0799     Document Type: Article

References (35)

1. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 1998;67:71-98.
2. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404:42-9.
3. Cooperman BS, Kashlan OB. A comprehensive model for the allosteric regulation of class la ribonucleotide reductases. Adv Enzyme Regul 2003;43: 167-82.
4. Cory JG, Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol Cell Biochem 1983;53-4:257-66.
5. Wright JA, Chan AK, Choy BK, et al. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis. Biochem Cell Biol 1990;68:1364-71.
6. Ochiai E, Mann GJ, Graslund A, Thelander L. Tyrosyl free radical formation in the small subunit of mouse ribonucleotide reductase. J Biol Chem 1990;265: 15758-61.
7. Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 1988;57: 349-74.
8. Shao J, Zhou B, Zhu L, et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 2004;64:1-6.
9. Guittet O, Hakansson P, Voevodskaya N, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001; 276:40647-51.
10. Zhou B, Shao J, Su L, et al. A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases. Mol Cancer Ther 2005;4:1830-6.
11. Yamaguchi T, Matsuda K, Sagiya Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61: 8256-62.
12. Nakano K, Balint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000;19:4283-9.
13. Liu X, Zhou B, Xue L, et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol 2004;67: 1499-511.
14. Currie RA. NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF. J Biol Chem 1998; 273:1430-4.
15. Filatov D, Thelander L. Role of a proximal NF-Y binding promoter element in S phase-specific expression of mouse ribonucleotide reductase R2 gene. J Biol Chem 1995;270:25239-43
16. Chabes AL, Bjorklund S, Thelander L. S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem 2004;279:10796-807.
17. Xue L, Zhou B, Liu X, et al. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 2003;63:980-6.
18. Engstrom Y, Eriksson S, Jildevik I, et al. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 1985;260:9114-6.
19. Liu X, Zhou B, Xue L, et al. The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells. Biochem Pharmacol 2005;70:1288-97.
20. Zhou B, Liu X, Mo X, et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 2003;63:6583-94.
21. Huntington JT, Shields JM, Der CJ, et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 2004;279:33168-76.
22. Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci U S A 1996;93:14036-40.
23. Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998;58:1650-3.
24. Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998;16:43-9.
25. Fan H, Huang A, Villegas C, Wright JA. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci U S A 1997;94:13181-6.
26. Zhou BS, Ker R, Ho R, et al. Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem Pharmacol 1998;55:1657-65.
27. Decraene D, Smaers K, Maes O, et al. A low UVB dose, with the potential to trigger a protective p53-dependent gene program, increases the resilience of keratinocytes against future UVB insults. J Invest Dermatol 2005;125:1026-31.
28. Ohno K, Tanaka-Azuma Y, Yoneda Y, Yamada T. Genotoxicity test system based on p53R2 gene expression in human cells: examination with 80 chemicals. Mutat Res 2005;588:47-57.
29. Tsai MH, Chen X, Chandramouli GV, et al. Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene 2006; 25:622-32.
30. Yoshida T, Haga S, Numata Y, et al. Disruption of the p53-53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis. Int J Cancer 2006; 118:1395-403.
31. Bergamini CM, Gambetti S, Dondi A, Cervellati C. Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 2004;10:1611-26.
32. Shiu CT, Lee TM. Ultraviolet-B-induced oxidative stress and responses of the ascorbate-glutathione cycle in a marine macroalga Ulva fasciata. J Exp Bot 2005;56:2851-65.
33. Jackson JH. Potential molecular mechanisms of oxidant-induced carcinogenesis. Environ Health Perspect 1994; 102 Suppl 10:155-7.
34. Oliveira CJ, Schindler F, Ventura AM, et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Radic Biol Med 2003;35:381-96.
35. Xue L, Zhou B, Liu X, et al. Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res 2006;66:1900-5.